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Arterial stiffening is a risk factor for cardiovascular
disease, but how arteries stay supple is unknown.
Here, we show that apolipoprotein E (apoE) and
apoE-containing high-density lipoprotein (apoE-
HDL) maintain arterial elasticity by suppressing
the expression of extracellular matrix genes. ApoE
interrupts a mechanically driven feed-forward loop
that increases the expression of collagen-I, fibro-
nectin, and lysyl oxidase in response to substratum
stiffening. These effects are independent of the
apoE lipid-binding domain and transduced by Cox2
and miR-145. Arterial stiffness is increased in apoE
null mice. This stiffening can be reduced by admin-
istration of the lysyl oxidase inhibitor BAPN, and
BAPN treatment attenuates atherosclerosis despite
highly elevated cholesterol. Macrophage abundance
in lesions is reduced by BAPN in vivo, andmonocyte/
macrophage adhesion is reduced by substratum
softening in vitro. We conclude that apoE and
apoE-containing HDL promote healthy arterial bio-
mechanics and that this confers protection from
cardiovascular disease independent of the estab-
lished apoE-HDL effect on cholesterol.INTRODUCTION
The mechanobiology of cells and tissues is a rapidly developing
field of importance to development, physiology, and disease
(Davies, 2009; Discher et al., 2005; Egeblad et al., 2010; Gar-
cia-Cardena and Gimbrone, 2006; Schwartz and DeSimone,
2008). Increases in tissue stiffness and intracellular tension are
common features of fibrosis-associated processes such as
wound repair, cancer, and cardiovascular disease (CVD) (Duprez
and Cohn, 2007; Levental et al., 2009). A recurring theme
in these processes is remodeling of the extracellular matrixCell Re(ECM). Increased ECM synthesis is mediated by fibrotic factors
such as TGF-b and PGF2 (Border and Noble, 1994; Oga et al.,
2009), but whether antifibrotic factors exist to antagonize
aberrant ECM gene expression and maintain normal tissue
elasticity is poorly understood.
Mechanical forces play a major role in the pathogenesis of
atherosclerosis (Davies, 2009; Garcia-Cardena and Gimbrone,
2006; Gimbrone et al., 2000). As a result of disturbed blood
flow patterns at sites of arterial curvature and branches, endo-
thelial cell integrity is disrupted focally, ultimately allowing for
entry of blood monocytes into the vessel. These monocytes
develop into macrophages and foam cells, a process exacer-
bated by high cholesterol, and then secrete cytokines that act
on vascular smooth muscle cells (VSMCs) to promote their
dedifferentiation to a migratory and proliferative phenotype.
Dedifferentiated VSMCs synthesize large amounts of ECM
components (in particular, fibrillar collagens and elastin) and
matrix-modifying enzymes that remodel the local ECM (Owens
et al., 2004; Thyberg et al., 1997; Thyberg et al., 1990). Elastin
makes arteries more compliant to large deformations, and
fibrillar collagens make arteries stiffer (Dı´ez, 2007; Lakatta,
2007). Themechanical properties of elastin and fibrillar collagens
depend upon their crosslinking by the lysyl oxidases (Csiszar,
2001; Kagan and Li, 2003). VSMCs produce lysyl oxidase and
are therefore poised to be major regulators of matrix remodeling
and arterial stiffness.
Arterial stiffness increases with normal aging, and this pro-
cess is exaggerated by the metabolic syndrome and diabetes
(Lakatta, 2007; Stehouwer et al., 2008). Arterial stiffness is also
a cholesterol-independent risk factor for a first cardiovascular
event (Mitchell et al., 2010). Arterial stiffness is determined by
vascular tone and the amount and composition of the ECM.
While regulators of vascular tone have been very well studied
(Bellien et al., 2008), little is known about effectors and mecha-
nisms that might regulate arterial stiffness by limiting ECM
production. Nor is it known if arterial stiffening is a cause or
consequence of cardiovascular disease.
Here, we show that the expression of ECM genes in VSMCs
and arterial stiffness is potently suppressed by apolipopro-
tein E (apoE) and apoE-containing high-density lipoproteinports 2, 1259–1271, November 29, 2012 ª2012 The Authors 1259
Figure 1. Altered ECM Gene Expression in ApoE Null Mice
(A) Heat map of collagen and Lox genes in WT and apoE null aortae. Duplicates represent Agilent dye-swaps. Asterisks indicate fold-changeR2 in athero-prone
(P/P) and resistant (R/R) regions. Scale: 0.9 to 1.0.
(B) Cleaned aortae from 6-month-old male WT and apoE null mice analyzed by real-time qPCR. Results show mean ± SE, n = 4. p = 0.012 by two-tailed t test.
(C and D) Cleaned aortae analyzed for hydroxyproline content (mean ± SD, n = 3) or western blotted for FN, respectively.
(E) Lox immunostaining (red) of uninjured and injured femoral arteries. DAPI-stained nuclei are shown in blue. Dashed lines show the IEL and EEL. M, media; NI,
neointima. Middle panels show enlargements of boxed regions. Scale bar represents 50 mm.
(F) Thoracic aortae of four 6-month-old WT and four apoE null mice were cleaned of adventitia, opened longitudinally, and analyzed by AFM, indenting into the
luminal surface at > 20 distinct nonlesioned locations. The mean elastic modulus was calculated for each mouse and graphed as a Tukey box and whisker plot;
p = 0.029 by two-tailed Mann-Whitney test.
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(apoE-HDL). ApoE-HDL has a well-established role in removing
cholesterol from peripheral cells and delivering it to the liver in
a process called reverse cholesterol transport, but several
reports using cultured cells have indicated that the effects of
apoE extend beyond regulation of plasma lipid levels (Ishigami
et al., 1998, 2000; Kothapalli et al., 2004; Swertfeger and Hui,
2001; Symmons et al., 1994). Early in vivo studies even sug-
gested that a lipid-independent effect of apoE could protect
against atherosclerosis (Thorngate et al., 2003), though the
basis for this observation has remained elusive. We now show
that the inhibitory effect of apoE-HDL on ECM gene expression
and arterial stiffening is cholesterol-independent and sufficient
to attenuate atherosclerosis. Thus, in addition to its established
effect on reverse cholesterol transport, HDL contributes to
healthy arterial biomechanics, and this effect is causal for
cardiovascular protection.
RESULTS
ECM Gene Expression Suppressed by ApoE and HDL
We interrogated GEO data set GSE13865 that transcript
profiled atherosclerosis-prone and atherosclerosis-resistant
regions of 4-month-old wild-type (WT) and apoE null mouse
aortae (Figure 1A). Genes that were differentially expressed in
the athero-prone regions were identified and subjected to
enrichment analysis against the Gene Ontology (GO) database.
This analysis ranked ‘‘Extracellular Region’’ (GO: 0005576) and
‘‘Extracellular Region Part’’ (GO: 0044421) as the most enriched
within the ‘‘Cellular Component’’ (GO: 0005575) functional
grouping (Figure S1A). Within the ‘‘Extracellular Region Part,’’
two functional groups were highly enriched: the ‘‘Extracellular
Matrix’’ (GO: 0031012) and ‘‘Plasma Lipoprotein Particles’’
(Figure S1B), the latter of which was expected given the dele-
tion of apoE. Several collagen genes, including the highly ex-
pressed type I collagen, were differentially expressed in apoE
null aortae (Table S1A; Figure 1A, asterisks).
The effect of apoE knockout on several collagen mRNAs was
confirmed by real-time quantitative PCR (qPCR) (Figure 1B;
Table S1B). Real-time qPCR also revealed an apoE-dependent
regulation of fibronectin (FN) mRNA that was not detected by
transcript profiling (Figure 1B). Collagen protein (measured as
hydroxyproline content) and FN protein levels were increased
in the aortae of apoE null mice as compared to WT controls
(Figures 1C and 1D, respectively). Similarly, increased
collagen-I protein was readily detected in the media and neoin-
tima of immunostained aortic root sections from apoE null, but
not WT, mice (Figure S1C). In contrast, elastin mRNA levels
were not strongly affected by deletion of apoE (Figure S1D;
Tables S1A and S1C).
Lysyl oxidase (Lox) crosslinks adjacent collagen triple helices
and confers tensile strength to the collagen fibril (Csiszar, 2001;
Kagan and Li, 2003). Our transcript profiling analysis revealed(G) Cleaned aortae from 6-month-old male WT and apoE null mice were divide
from the aortae and analyzed by real-time qPCR for collagen-I, FN, and Lox gen
n = 5. p = 0.036 by two-tailed t test.
See also Figure S1 and Tables S1A–S1C.
Cell Rean increase in the expression of Lox mRNA in apoE null arteries
as compared to WT (Figure 1A, asterisk). Lox mRNA and protein
induction in apoE null arteries was confirmed by real-time qPCR
and immunostaining (Figures 1B and 1E, respectively; Table
S1A). Note the increased Lox protein in apoE null versus WT
arteries (Figure 1E, top and middle panels), and even greater
increased expression in the media and neointima of apoE null
mice after fine wire femoral artery injury (Figure 1E, bottom
panels). In contrast, the gene expression of procollagen-
lysine,2-oxoglutarate 5-dioxygenase 3 (PLOD3), which catalyzes
the hydroxylation of lysine residues in collagens, was similar
in WT and apoE null arteries (Figure S1E). Upregulation of
collagen-I protein and enhanced crosslinking by elevated Lox
expression has the potential to increase tissue stiffness; indeed,
atomic force microscopy (AFM) in force mode showed an
increase in the median elastic modulus of apoE null femoral
arteries as compared to WT controls (Figure 1F). Further studies
focused on collagen-I and Lox, which regulate tensile strength
and tissue elasticity, and FN, which interacts with collagen
functionally and has been associated with stiffness-dependent
cell proliferation (Bru¨el et al., 1998; Kadler et al., 2008; Kagan
and Li, 2003; Klein et al., 2009).
Deletion of apoE in mice leads to hyperlipidemia and sponta-
neous atherosclerosis as well as an exaggerated response to
vascular injury (Ali et al., 2007; Matter et al., 2006; Piedrahita
et al., 1992; Plump et al., 1992). Since VSMCs dedifferentiate
at sites of injury and atherosclerotic lesion formation and begin
to produce relatively large amounts of ECM, we considered the
possibility that the matrix-regulatory effects detected in apoE
null mice were secondary to lesion formation. However, several
lines of evidence collectively indicated that the changes we
observed in collagen-I, FN, and Lox gene expression were not
merely consequences of disease. First, we could restore apoE
expression in the liver of young apoE null mice by infection
with AAV-apoE3 (Kitajima et al., 2006), and this resulted in
near-WT levels of Col1a1, Col1a2, FN, and Lox gene expression
quickly (within 2 weeks; compare Figures S1F and S1G to S1H
and S1I). Second, the Col1a2, FN, and Lox genes were similarly
upregulated in athero-resistant as well as athero-prone regions
of the apoE null aortae as compared to WT (Figure 1A, asterisks,
and Figure 1G; Table S1C). Third, purified apoE3, at a physiolog-
ical concentration (Wientgen et al., 2004), reduced levels of
Col1a1, Col1a2, FN, and Lox protein (Figures 2A and 2B) and
mRNAs (Figures 2C–2F) in cultured VSMCs: these effects were
specific to dedifferentiated VSMCs (Figure 2B) and dose and
time dependent (Figures S2A–S2D). We conclude that apoE
has a primary suppressive effect on expression of the VSMC
collagen-I, FN, and Lox genes. A similar pattern of inhibition
was seen in human VSMCs but not human aortic endothelial
cells (Figures S2E and S2F).
The majority of apoE circulates as a component of triglyc-
eride-rich lipoproteins and HDL, but apoE is not present ind into arch (ascending) and thoracic (descending) regions. RNA was isolated
e expression. Results are normalized to 18S rRNA. Results show mean ± SE,
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Figure 2. ApoE and HDL Inhibit ECM Expression in Dedifferentiated VSMCs
(A) Serum-starved VSMCs isolated from WT mice were incubated with 10% FBS in the absence (control; C) or presence of 2 mM apoE3 for 24 hr. The cells were
fixed and stained for collagen-I, FN, or Lox and visualized by immunofluorescencemicroscopy. Scale bar represents 50mm. The IgG control used FBS-stimulated
cells.
(B) VSMCs were isolated from C57BL/6 aortae by explant cultures (dedifferentiated phenotype) or by collagenase digestion (differentiated phenotype).
Asynchronous cells of each phenotype were incubated with 10% FBS in the absence (control, C) or presence of 2 mM apoE3 for 24 hr and then stained for
collagen-I (red). Blue: DAPI-stained nuclei. Scale bar represents 50 mm. The figure shows a representative result.
(C and D) Serum-starved VSMCs isolated from WT mice were incubated with 10% FBS in the absence (control, C) or presence of 2 mM apoA-I or apoE3 or
50 mg/ml HDL or LDL for 24 hr. RNA levels were determined by real-time qPCR.
(E and F) The experiment in (C) and (D) was repeated except we compared the effects of 2 mM apoE3 to its N- and C-terminal fragments.
Real-time qPCR results show mean ± SD of duplicate PCR reactions and are representative of at least three independent experiments.
See also Figure S2.low-density lipoprotein (LDL). We therefore compared HDL
and LDL for their abilities to regulate matrix protein gene ex-
pression in primary mouse VSMCs. HDL efficiently suppressed
collagen-1, FN, and Lox gene expression, while LDL failed to
inhibit these genes (Figures 2C and 2D). ApoA-I, the major
apolipoprotein in HDL, was unable to decrease expression of1262 Cell Reports 2, 1259–1271, November 29, 2012 ª2012 The Autthese matrix genes (Figures 2C and 2D), nor was HDL after
depletion of apoE (Figure S2G). All three isoforms of human
apoE inhibited ECM gene expression (Figure S2H). Thus,
suppression of collagen-I, FN, and Lox gene expression is
a selective property of apoE and apoE-containing HDL rather
than a general property of apolipoproteins and lipoproteins.hors
ApoE3 consists of a 22 kDa N-terminal domain that binds to the
LDL receptor and a 10 kDa C-terminal domain required for
lipid binding and regulation of reverse cholesterol transport
(Weisgraber, 1994). Expression of Col1a1, Col1a2, FN, and
Lox mRNAs were all repressed by the N-terminal domain but
not by the C-terminal lipid-binding domain of apoE3 (Figures
2E and 2F).
Mechanosensitive Collagen-I and Fibronectin Gene
Expression Regulated by Cox2 and Circumvented
by ApoE
Collagen-I expression correlates directly with ECM stiffness in
fibroblasts (Liu et al., 2010). We therefore asked if the effects
of apoE on ECM gene expression might be affected by
substratum stiffness itself. VSMCs were cultured on biocompat-
ible FN-coated polyacrylamide hydrogels prepared with elastic
moduli that span the stiffness range of healthy and diseased
arteries (2,000 and 25,000 Pa; Klein et al., 2009; hereafter
called low and high stiffness, respectively). The expression of
Col1a1, CoI1a2, FN, and Lox mRNAs (Figures 3A and 3B) as
well as Lox enzymatic activity (Figure S3A) were all positively
regulated by substratum stiffness, and this stiffness-dependent
upregulation was blocked by apoE3 (Figures 3A, 3B, and S3A).
We conclude that apoE is an inhibitor of mechanosensitive
ECM gene expression.
Collagen-I gene expression is inversely proportional to the
expression of Cox2 in fibroblasts (Liu et al., 2010) and VSMCs
(Figures 3A versus 3E; Figures S2E versus S2F). Previously, we
reported that apoE3 and its N-terminal domain stimulate the
expression of Cox2 mRNA and protein in VSMCs (Ali et al.,
2008; Kothapalli et al., 2004). Consistent with these results,
the Cox2 inhibitor, nimesulide, prevented suppression of the
collagen-I and FN genes by apoE3 in VSMCs whereas the
Cox1 inhibitor, SC560, was without effect (Figure 3C). Cox2
production in VSMCs leads to the production of PGI2, and
VSMCs treated with apoE3 have increased amounts of PGI2 in
their conditioned medium (Ali et al., 2008; Kothapalli et al.,
2004). The PGI2 mimetic, cicaprost, phenocopied the effect of
apoE3 on collagen-I and FN mRNAs (Figures 3D, S3C, and
S3D), and these effects of apoE3 and PGI2 are linked mechanis-
tically because deletion of the PGI2 receptor, called IP, pre-
vented suppression of Col1a1, Col1a2, and FN mRNAs by
apoE (Figures 3D, S3C, and S3D). Thus, regulation of VSMC
collagen-I and FN gene expression by apoE is mediated by the
Cox2-PGI2-IP signaling pathway.
If Cox2 is causally linked to the effect of apoE3 on mechani-
cally driven collagen-I and FN gene expression, then its
response to apoE3 should be mechanosensitive. Indeed, we
found that Cox2 levels (Figure 3E) and activity (Figure S3B)
decline when VSMCs are cultured at a high stiffness character-
istic of vascular lesions. ApoE3 prevents this downregulation
and maintains elevated Cox2 gene expression (Figure 3E) and
enzymatic activity (Figure S3B) despite substrate stiffening.
Moreover, the apoE3 effect on mechanosensitive Cox2 expres-
sion can explain the suppressive effects of apoE3 on collagen-I
and FN gene expression because (1) Cox2 inhibition with nime-
sulide was sufficient to increase levels of collagen-I and FN
mRNAs in cells cultured on a low stiffness substratum (Figure 3F),Cell Reand (2) ectopic expression of Cox2 was sufficient to reduce
levels of collagen-I and FN mRNAs in VSMCs cultured on a rigid
substratum (Figure 3G). Thus, the downregulation of Cox2 on
a stiff substratum leads to increased collagen-I and FN gene
expression in VSMCs, and apoE limits synthesis of these
ECM proteins by preventing the stiffness-dependent down-
regulation of Cox2 (Figure 3H). Similar results were seen with
collagen-coated hydrogels (Figures S3E and S3F), indicating
that the effects were stiffness-specific rather than matrix-protein
specific.
We considered the possibility that the suppressive effects of
apoE3 and/or a soft substratum on ECM mRNAs might be due
to increased VSMC differentiation because ECM synthesis
is minimal in differentiated (also called ‘‘contractile’’) VSMCs
(Owens et al., 2004; Thyberg et al., 1990, 1997). However,
three different markers of differentiated VSMCs were slightly
decreased, rather than increased, in response to a low-stiffness
substratum (Figure S3G) and apoE3 had no effect on SM-marker
expression regardless of substratum stiffness (Figure S3G).
Thus, apoE3 directly controls mechanosensitive ECM pro-
duction in dedifferentiated VSMCs rather than indirectly inhibit-
ing ECM synthesis downstream of a primary effect on VSMC
differentiation.
miR-145 Mediates the Suppressive Effect
of ApoE on Lox Gene Expression
In contrast to collagen-I and FN, ectopic expression of Cox2
on a rigid substratum (Figure 3G) or Cox2 inhibition on a soft
substratum (Figure S4A) failed to alter Lox gene expression.
Deletion of IP (Figure S4B) or inhibition of Cox2 also failed to
overcome the inhibitory effect of apoE3 on Lox gene expression
(Figure S4C) or enzymatic activity (Figure S4D). Thus, the effect
of apoE3 on mechanosensitive Lox gene expression is Cox2
independent. We used a genome-wide approach to identify
potential upstream regulators of Lox gene expression in vivo.
We injured the femoral arteries of smooth muscle actin (SMA)-
GFP transgenic mice, a line in which GFP levels are controlled
by the a-SMA promoter (Yokota et al., 2006). Injury-induced
VSMC proliferation can be visualized in this mouse line by the
loss of GFP fluorescence because the SMA promoter is not
expressed in proliferating (dedifferentiated) VSMCs (Klein et al.,
2009). We microdissected these GFP-negative femoral artery
regions and determined global mRNA expression patterns
relative to uninjured contralateral controls. Differentially ex-
pressed mRNAs and miRNAs were superimposed on the
Ingenuity database of molecules experimentally demonstrated
or highly predicted to regulate Lox. This analysis identified
miR-145 as a putative direct upstream Lox mRNA regulator
(Figure 4A, box).
miR-145 levels were strongly reduced in apoE null arteries as
compared to WT (Figure 4B), consistent with upregulation of
Lox mRNA seen under the same conditions (refer to Figure 1B).
Moreover, apoE3 increased miR-145 in cultured VSMCs (Fig-
ure 4C), consistent with the downregulation of Lox mRNA (refer
to Figure 2D). This inverse relationship between miR-145 and
Lox mRNA is causal, because ectopic miR-145 expression
reduced Lox mRNA levels whereas an anti-miR-145 blocked
the upregulation of Lox mRNA in response to apoE3 (Figure 4D).ports 2, 1259–1271, November 29, 2012 ª2012 The Authors 1263
Figure 3. Mechanosensitive Gene Expression Regulated by ApoE
For all panels, Col1a1, Col1a2, FN, Lox, or Cox2 mRNAs were quantified by real-time qPCR and plotted relative to 18S rRNA. For panels (A)–(G), results show
mean ± SD of duplicate PCR reactions and are representative of at least three independent experiments.
(A and B) Serum-starved primary mouse VSMCs were incubated with 10% FBS in the absence (control, C) or presence of 2 mM apoE3 on high stiffness or low
stiffness FN-coated hydrogels for 24 hr.
(C) The experiment in (A) and (B) was repeated except that apoE-treated VSMCs on plastic were given 1 mM nimesulide (Nimes; Cox2 inhibitor) or 1 mM SC560
(Cox1 inhibitor).
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Neither collagen-I nor FN mRNA levels were affected by ectopic
expression or inhibition of miR-145 (Figure 4E and SF4E). Thus,
miR-145 induction selectively transduces the apoE3 signal to
repress Lox mRNA. The combined effects of apoE3 on Cox2
and miR-145 account for its regulation of the collagen-I, FN,
and Lox genes (Figure 4F).
Inhibition of Arterial Stiffening Reduces Atherosclerosis
If suppression of ECM expression and arterial stiffening
contribute to the cardiovascular protective effect of apoE, then
a blockade of arterial stiffening should reduce atherosclerosis
in apoE null mice. ApoE null mice on a high-fat diet were treated
with the selective lysyl oxidase inhibitor, BAPN (Bru¨el et al., 1998;
Kagan and Li, 2003; Tang et al., 1983). The lysyl oxidase family
crosslinks collagen fibers and confers its tensile properties
(Brasselet et al., 2005; Bru¨el et al., 1998; Wells, 2008). Lysyl
oxidases also crosslink elastin, but several studies have shown
that the net effect of BAPN treatment has been a reduction in
tissue stiffness (Bru¨el et al., 1998). Blood pressure is not affected
by BAPN (Berry et al., 1981; Iwatsuki et al., 1977; Kanematsu
et al., 2010).
We treated apoE null mice on a high-fat diet with vehicle or
BAPN. BAPN led to a notable reduction in arterial stiffness as
compared to vehicle-treated controls (Figure 5A). BAPN also
inhibited the development of atherosclerosis as determined by
Oil Red O-staining of isolated aortae (Figures 5B and 5C). More-
over, the degree to which lesion formation was reduced (50%)
agreed reasonably well with the degree to which BAPN reduced
arterial stiffness (Figure 5A). These inhibitory effects occurred
despite the extraordinary high plasma cholesterol levels seen
in apoE null mice on a high-fat diet (Figure 5D). Body weight
was unaffected by BAPN (Figure 5E). Thus, the inhibitory effect
of apoE on arterial stiffness confers protection against athero-
sclerosis, and pharmacologic regulation of arterial biomechanics
can attenuate disease even when plasma cholesterol remains
extremely high.
BAPN also reduced lesion area in aortic roots (Figures 6A
and 6B), and the magnitude of the effect was similar to what
we observed in the thoracic aorta. We then analyzed the compo-
sition of these aortic root lesions. Second harmonic generation
two-photon microscopy revealed a clear reduction in highly
structured collagen within the neointimas of lesions from the
BAPN-treated mice (Figure 6C, top panel; Figure 6D, left)
whereas total collagen-I levels were minimally affected (Fig-
ure 6C, bottom panels; Figure 6D, right). We observed chimeric
staining patterns for a-SMA (a marker of differentiated VSMCs)
in lesions regardless of BAPN treatment (Figures 7A and 7B).
However, CD68-staining revealed that macrophage abundance
in lesions was markedly reduced in the BAPN-treated mice(D) The experiment in (C) was repeated using WT and IP null VSMCs treated with
(E) The experiment in (A) was analyzed for Cox2 mRNA.
(F) Serum-starved primary mouse VSMCs were incubated with 10% FBS in the
stiffness FN-coated hydrogels for 24 hr.
(G) Primary VSMCswere isolated frommice expressing Cre-dependent Cox2. The
with adenoviruses encoding LacZ or Cre, and directly stimulated with 10% FBS
(H) Model of the stiffness- and apoE-regulatory effects on Cox2, collagen-I, FN,
See also Figure S3.
Cell Re(Figures 7A and 7B). We then prepared ECM-coated hydrogels
at the stiffness of healthy and diseased arteries to determine if
the adhesion of THP-1 monocytes (Figure 7C) or primary mouse
thioglycollate-elicited peritoneal macrophages (Figure 7D) was
affected by substratum stiffness. Although the extent of cell
adhesion depended on the subendothelial ECM protein used
to prepare the hydrogel, in every case cell adhesion to ECM
was strongly reduced when we softened the ECM from the
high stiffness of lesions to the low stiffness of healthy arteries
(Figures 7C and 7D). Thus, the effect of BAPN on macrophage
abundance in vivo can be phenocopied by direct manipulation
of ECM stiffness in vitro. Collectively, these results reveal
a specific aspect of atherogenesis affected by arterial stiffness
and connect stromal ECM production and arterial stiffening to
the inflammatory component of lesion development.
DISCUSSION
Our results identify apoE and apoE-containing HDL as negative
regulators of ECM gene expression and arterial stiffening. This
effect does not require the apoE lipid binding domain and
confers cardiovascular protection independent of plasma
cholesterol levels. We detected the suppressive effect of apoE
on collagen-I, FN, and Lox expression selectively in dedifferenti-
ated VSMCs. This result suggests that apoE-HDL does not affect
homeostatic arterial stiffness in contractile VSMCs, but rather
acts when dedifferentiated VSMCs begin to synthesize ECM
and stiffen their microenvironment during the onset of CVD.
Mechanosensitive Regulation of Cox2 and Lox
Expression Opposed by ApoE-HDL
Our initial transcript profiling results, as well similar results by
others (Hui and Basford, 2005), suggested that apoE would be
an overall inhibitor of ECM gene expression. However, a more
detailed analysis of apoE action on deformable substrata indi-
cated that apoE-HDL actually has a much more subtle role,
and that it selectively interferes with the increase in collagen-I,
FN, and Lox gene expression that occurs in response to sub-
stratum stiffening (Figure 4F). These results suggest the exis-
tence of a mechanically sensitive feed-forward loop that can
accelerate ECM synthesis, matrix remodeling, and arterial stiff-
ening (Figure 4F). By short-circuiting this loop, apoE-HDL would
restrain stiffening during the progression of atherosclerosis.
Cox2 regulates the production of PGI2 in VSMCs, and PGI2
inhibits collagen-I and FN gene expression. Moreover, Cox2
gene expression is mechanosensitive, with efficient expression
seen only when VSMCs are on soft surfaces characteristic of
normal arteries. We posit that the inverse relationship between
ECM stiffness and Cox2 expression represses collagen-I/FN2 mM apoE3 or 200 nM cicaprost (Cica; stable PGI2 mimetic).
absence (control, C) or presence of 1 mM nimesulide on high stiffness or low
cells were seeded overnight on FN-coated coverslips, serum-starved, infected
for 24 hr.
and Lox expression.
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Figure 4. miR145-Dependent Lox Gene Expression by ApoE
(A) Upstream regulators of Lox showing differential gene expression after vascular injury as determined by Ingenuity Pathway Analysis. Green and red represent
induction and repression, respectively.
(B) Aortae from 6-month-old WT or apoE null mice were harvested and analyzed by real-time qPCR for miR-145. Results show mean ± SE, n = 4, p = 0.0002 by
two-tailed t test.
(C) Serum-starved primary mouse VSMCs were incubated with 10% FBS in the absence (control, C) or presence of 2 mM apoE for 24 hr. RNA was isolated and
analyzed by real-time qPCR for miR-145.
(D and E) VSMCs were transfected with pmiR-145 or anti-miR-145, serum starved for 48 hr and stimulated with 10% FBS in the absence (control, C) or presence
of 2 mM apoE3 for 24 hr. RNA was isolated and analyzed by real-time qPCR for Lox, Col1a1, and FN.
(F) Regulation of collagen-I, FN, and Lox gene expression by apoE through Cox2 and miR-145.
In (C–E), results show mean ± SD of duplicate PCR reactions and are representative of at least three independent experiments.
See also Figure S4.synthesis and contributes to healthy compliance in healthy
vessels (Figure 4F). Upon an atherogenic insult, however, the
efficacy of this mechanism is reduced as dedifferentiated
VSMCs accumulate and ECM production increases. ApoE-
HDL helps to maintain negative feedback on collagen-I and FN1266 Cell Reports 2, 1259–1271, November 29, 2012 ª2012 The Autsynthesis by circumventing mechanical control of Cox2 gene
expression (Figure 4F). In apoE null mice, and perhaps in humans
with insufficient apoE-HDL, the stiffening-dependent loss of
Cox2 would proceed unabated and exacerbate ECM synthesis,
arterial stiffening, and lesion development. Since Cox2 limitshors
Figure 5. Reduced Atherosclerosis in ApoE
Null Aortae Softened In Vivo with BAPN
(A) AFMof aortae from2-month-old old apoE null
mice fed a high-fat diet and treated with vehicle
(PBS; n = 5) or BAPN (n = 4) for 16 weeks. Data are
presented as a Tukey box and whisker plot with
a 1-tailed Mann-Whitney test for softening by
BAPN; p = 0.032.
(B and C) Oil red O staining and lesion quantifi-
cation in aortae of apoE null mice treated with PBS
(n = 17) or BAPN (n = 15). Data are presented as
Tukey box and whisker plots; p = 0.019 by two-
tailed Mann-Whitney test. Scale bar represents
1 mm.
(D) Plasma cholesterol levels (mean ± SD) in PBS
(n = 10) andBAPN (n = 9) treatedmicemeasured at
the time of sacrifice. The arrow shows the
cholesterol level in wild-type mice on a western
diet (Nakashima et al., 2004).
(E) Mice treated with PBS (n = 17) or BAPN (n = 17)
from both groups were weighed every 4 weeks
until sacrifice. p > 0.05 by two-way ANOVA.
Results show mean ± SD.collagen-I expression, an increase in arterial stiffness may be
a contributing factor to the cardiovascular hazards associated
with chronic use of selective Cox2 inhibitors (FitzGerald, 2003).
ApoE also suppresses Lox expression in VSMCs. The effect of
apoE on Lox is independent of Cox2 but strongly dependent on
the upregulation of miR-145. It is not yet know if apoE-HDL
signaling to miR-145 and Cox2 involves distinct apoE receptors
or divergent signaling downstream of a single receptor. The
best-studied apoE receptors are LDL receptor (LDLR), LRP,
and heparin sulfate proteoglycan (Boucher et al., 2003; Nimpf
and Schneider, 2000; Strickland et al., 2002). Our previous report
indicated that Cox2 induction by apoE is likely independent of
these receptors (Ali et al., 2008). Downregulation of miR-145
and its bicistronic partner, miR-143, has been implicated in the
phenotypic switch of VSMCs from contractile (differentiated) to
synthetic (dedifferentiated) states (Boettger et al., 2009; Cordes
et al., 2009). Consistent with these reports, we saw a large
decrease in miR-145 at sites of vascular injury, a setting in which
VSMC dedifferentiation is occurring. However, apoE3 strongly
increases miR-145 but does not affect smooth muscle differen-
tiation as judged by our marker analysis. Thus, miR-145 downre-
gulationmay contribute to the dedifferentiation of VSMCs, but its
upregulation is insufficient for VSMC differentiation. The collec-
tive work of others (Boettger et al., 2009; Cordes et al., 2009;
Xin et al., 2009) also suggests a complex and incompletely
understood role for miR-145 in VSMC differentiation.Cell Reports 2, 1259–1271, NoImplications for HDL Biology
Many studies have concluded that HDL
protects against cardiovascular disease,
and pharmacological treatments and/or
lifestyle changes that elevate HDL have
become engrained into Western medical
practice. Canonically, HDL is thought to
confer cardiovascular protection by stim-
ulating reverse cholesterol transport, themovement of excess cholesterol from peripheral tissues back
to the liver for excretion from the body (Mahley et al., 2006; Roth-
blat and Phillips, 2010). However, two major studies have
recently questioned the importance of high HDL levels in cardio-
vascular protection. One clinical study, AIM-HIGH, increased
HDL in response to slow-delivery niacin yet failed to show
reduced cardiovascular risk (Nicholls, 2012; Nofer, 2012). More-
over, a large-scale mendelian randomization analysis found that
increases in plasma HDL are not sufficient to reduce the risk of
myocardial infarction (Voight et al., 2012). Our data may help to
reconcile these conflicting reports because apoE-HDL is rela-
tively rare, comprising only 6% of the total HDL protein (Weis-
graber and Mahley, 1980). Cardiovascular protective effects
associated with elevated apoE-HDL may escape detection in
clinical and population genetics analyses that rely on changes
in total plasma HDL levels.
Arterial Biomechanics and CVD
Atherosclerosis develops focally at sites of disturbed flow
(Davies, 2009; Garcia-Cardena and Gimbrone, 2006; Gimbrone
et al., 2000). In this context, we note that Cox2 production
by endothelial cells is increased at sites of disturbed flow
(Dai et al., 2004), and that PGI2 is an important Cox2 product
of endothelial cells (Fitzgerald et al., 1987; Narumiya et al.,
1999) as it is in VSMCs. Thus, disturbed flow should enhance
PGI2 production focally, which could then act in a paracrinevember 29, 2012 ª2012 The Authors 1267
Figure 6. Reduced Collagen Structure and
Macrophage Abundance in Atherosclerotic
Lesions of BAPN-Treated Mice
(A and B) Oil red O staining and lesion quantifica-
tion in aortic roots of apoE null mice treated with
PBS (n = 15) or BAPN (n = 17). Data presented as
Tukey box and whisker plots; p < 0.0001 by two-
tailed Mann-Whitney test. Scale bar represents
200 mm.
(C) Second harmonic generation detection of
neointimal collagen. Top panels show composites
of three serial second harmonic generation (SHG)
images of an aortic root lesion from a PBS- or
BAPN-treated mouse; collagen SHG signal and
the elastin autofluorescence signal are pseudo-
colored green and red, respectively. Bottom
panels show composites of the same lesions
stained for total collagen-I (red) and nuclei (DAPI;
blue). Composite positions are indicated by
arrowheads. Scale bar represents 100 mm. NI,
neointima.
(D) Double-blind quantitation of lesion images
from mice treated with PBS (n = 18) and BAPN
(n = 19). Statistical significance was determined
by chi-square test.manner to limit collagen-I and FN synthesis by proximal dediffer-
entiated VSMCs. While this effect should be atheroprotective,
the fact that lesions prefer to form at sites of disturbed flow indi-
cates that reduced collagen and FN expression are not sufficient
to overcome other atherostimulatory effects of disturbed flow.
Nevertheless, our data do support the notion that loss of this
effect (e.g., in apoE null mice and perhaps humans with low
apoE-HDL) likely contributes to arterial stiffening and lesion
formation by reducing endothelial PGI2 production. Arterial
stiffness in vivo is regulated by vascular tone as well as ECM
composition, and PGI2 is a potent vasodilator (Fitzgerald et al.,
1987; Narumiya et al., 1999). Tone and ECM composition may
be linked through the Cox2-PGI2 pathway.
Monocyte/macrophage infiltration into the vessel wall con-
tributes profoundly to atherosclerosis because subendothelial
macrophages develop into the lipid-laden foam cells that popu-
late lesions. Circulating monocytes adhere to intimal endothelial
cells and begin the process of macrophage differentiation
and transmigration into the subendothelial space. Our in vivo
studies show that arterial stiffness is critical to this process.
Arterial softening with BAPN strongly reduces macrophage
abundance in lesions, and our hydrogel experiments show
that ECM softening inhibits the adhesion of monocytes and
macrophages to FN and collagen-IV, components of the suben-
dothelial ECM. Endothelial permeability is also sensitive to ECM
stiffness (Huynh et al., 2011). These results raise the possibility1268 Cell Reports 2, 1259–1271, November 29, 2012 ª2012 The Authorsthat pharmacological control of arterial
stiffness may complement the effect of
cholesterol-lowering drugs in treating
CVD by regulating the inflammatory
component of atherosclerosis. Although
the extrapolation of results from mice to
humans requires caution, our data fitwell with epidemiologic studies identifying arterial stiffness as
a cholesterol-independent risk factor for a first cardiovascular
event in humans (Duprez and Cohn, 2007; Mitchell et al., 2010).
EXPERIMENTAL PROCEDURES
Expression Profiling
Gene Expression Omnibus (GEO) data set GSE13865 was downloaded, pro-
cessed, and analyzed using Partek Genomics Suite. The same software was
used to determine differential gene expression in injured versus uninjured
arteries of SMA-GFP mice. Genes differentially expressed at sites of injury
were then analyzed using Ingenuity Pathway Analysis software (http://www.
ingenuity.com). See Extended Experimental Procedures for details.
Cell Culture
Primary explant murine VSMCs were isolated from 10- to 12-week-old male
C57BL/6 (WT), IP null, and conditional Cox2-expressing mice as described
(Cuff et al., 2001). Near confluent monolayers were serum-starved for 48 hr
before stimulation with 10% fetal bovine serum (FBS) with or without apolipo-
protein, lipoprotein, or cicaprost. Fibronectin-coated hydrogels were prepared
with elastic moduli that approximate the stiffness of healthy or diseased
arteries (Klein et al., 2009). Differentiated murine aortic VSMCs and thioglycol-
late-elicited peritoneal macrophages were isolated similarly to described
procedures (Golovina and Blaustein, 2006; Hodge-Dufour et al., 1997).
BAPN Treatment of ApoE Null Mice
The effect of BAPN on atherosclerosis was determined using 8-week-old
males fed a high-fat diet and given PBS or BAPN for 16 weeks. Aortae were
isolated from the heart to the diaphragm, and a small portion of the thoracic
Figure 7. Matrix Stiffness Regulates Mono-
cyte/Macrophage Adhesion to Substratum
(A) Aortic root lesions of apoE null mice treated
with PBS (n = 15) or BAPN (n = 16) were stained
with markers for macrophages (anti-CD68, red)
and VSMCs (anti-SMA, green). Scale bar repre-
sents 200 mm.
(B) Quantification of aortic root sections stained
positive for CD68 (p = 0.001) and SMA (p = 0.36).
Data are presented as Tukey box and whisker
plots. The p values are from two-tailed Mann-
Whitney tests.
(C and D) THP-1 monocytes (C) or primary murine
thioglycollate-elicited peritoneal macrophages (D)
were fluorescently labeled by incubation with
calcein-AM and added to high-stiffness (H) or
low-stiffness (L) ECM-coated hydrogels for 4 hr
at 37C. The total numbers of Calcein-AM labeled
cells were counted in five randomly selected
fields. Results show mean ± SD; n = 4. The
p values were determined by two-tailed t test.aortae near the diaphragm was used to determine the elastic modulus. The
remaining portions of aortae and the aortic roots were used to quantify
atherosclerotic lesion formation by Oil-Red O staining. Sectioned aortic roots
were also stained for CD68 and SMA. Blood was collected at the time of
sacrifice for determination of total plasma cholesterol levels. See Extended
Experimental Procedures for further details.
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